MEREO BIOPHARMA GROUP PLC Pre-Tax Income
MEREO BIOPHARMA GROUP PLC (MREO) reported Pre-Tax Income of -$7.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$7.00M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$6.72M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$7.35M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$7.02M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$41.88M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$43.25M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was -$30.00M.
- MEREO BIOPHARMA GROUP PLC income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$42.94M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.00M 10-Q · filed 2026-08-11 | -$13.72M 10-Q · filed 2026-08-11 | -$21.07M derived: sum of 3 quarters · filed 2026-08-11 | -$28.10M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$6.72M 10-Q · filed 2026-05-12 | -$14.07M derived: sum of 2 quarters · filed 2026-05-12 | -$21.09M derived: sum of 3 quarters · filed 2026-05-12 | -$35.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$14.38M derived: sum of 2 quarters · filed 2026-03-19 | -$28.99M derived: sum of 3 quarters · filed 2026-08-11 | -$41.88M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$7.02M 10-Q · filed 2025-11-10 | -$21.64M derived: sum of 2 quarters · filed 2026-08-11 | -$34.53M 10-Q · filed 2025-11-10 | -$41.57M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$14.62M 10-Q · filed 2026-08-11 | -$27.50M 10-Q · filed 2026-08-11 | -$34.55M derived: sum of 3 quarters · filed 2026-08-11 | -$49.55M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$12.89M 10-Q · filed 2026-05-12 | -$19.93M derived: sum of 2 quarters · filed 2026-05-12 | -$34.93M derived: sum of 3 quarters · filed 2026-05-12 | -$47.19M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$22.05M derived: sum of 2 quarters · filed 2026-03-19 | -$34.30M derived: sum of 3 quarters · filed 2026-03-19 | -$43.25M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$15.00M 10-Q · filed 2025-11-10 | -$27.26M derived: sum of 2 quarters · filed 2025-11-10 | -$36.21M 10-Q · filed 2025-11-10 | -$45.85M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$12.26M 10-Q · filed 2025-08-12 | -$21.21M 10-Q · filed 2025-08-12 | -$30.85M derived: sum of 3 quarters · filed 2025-08-12 | -$37.38M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$8.95M 10-Q · filed 2025-05-13 | -$18.59M derived: sum of 2 quarters · filed 2025-05-13 | -$25.12M derived: sum of 3 quarters · filed 2025-05-13 | -$26.87M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$9.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$16.17M derived: sum of 2 quarters · filed 2025-03-26 | -$17.92M derived: sum of 3 quarters · filed 2025-03-26 | -$30.00M 10-K · filed 2025-03-26 |
| 2023-09-30 | -$6.53M 10-Q · filed 2024-11-12 | -$8.28M derived: sum of 2 quarters · filed 2024-11-12 | -$20.36M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$1.75M 10-Q · filed 2024-08-13 | -$13.83M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$12.08M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$42.94M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |